| Genetic determinants of Parkinson's disease: can they help to stratify the patients based on the underlying molecular defect? S Redenšek, M Trošt, V Dolžan Frontiers in aging neuroscience 9, 20, 2017 | 48 | 2017 |
| Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson's disease S Redenšek, D Flisar, M Kojović, M Gregorič Kramberger, D Georgiev, ... Frontiers in pharmacology 10, 8, 2019 | 45 | 2019 |
| From genomics to omics landscapes of Parkinson's disease: revealing the molecular mechanisms S Redenšek, V Dolžan, T Kunej Omics: a journal of integrative biology 22 (1), 1-16, 2018 | 45 | 2018 |
| Molecular mechanisms related to responses to oxidative stress and antioxidative therapies in COVID-19: A systematic review EE Tsermpini, U Glamočlija, F Ulucan-Karnak, S Redenšek Trampuž, ... Antioxidants 11 (8), 1609, 2022 | 25 | 2022 |
| Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease S Redenšek, D Flisar, M Kojović, MG Kramberger, D Georgiev, Z Pirtošek, ... Journal of neuroinflammation 16, 1-12, 2019 | 25 | 2019 |
| Clinical-pharmacogenetic predictive models for time to occurrence of levodopa related motor complications in Parkinson’s disease S Redenšek, B Jenko Bizjan, M Trošt, V Dolžan Frontiers in genetics 10, 454938, 2019 | 15 | 2019 |
| The role of CTGF in liver fibrosis induced in 3D human liver spheroids SR Trampuž, S van Riet, Å Nordling, M Ingelman-Sundberg Cells 12 (2), 302, 2023 | 11 | 2023 |
| Assessment of the telomere length and its effect on the symptomatology of Parkinson’s disease T Levstek, S Redenšek, M Trošt, V Dolžan, KT Podkrajšek Antioxidants 10 (1), 137, 2021 | 10 | 2021 |
| Clinical and clinical-pharmacogenetic models for prediction of the most common psychiatric complications due to dopaminergic treatment in Parkinson’s disease S Redenšek, B Jenko Bizjan, M Trošt, V Dolžan International Journal of Neuropsychopharmacology 23 (8), 496-504, 2020 | 9 | 2020 |
| Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature S Redenšek Trampuž, D Vogrinc, K Goričar, V Dolžan Frontiers in molecular neuroscience 16, 1123955, 2023 | 8 | 2023 |
| Genetic factors associated with tardive dyskinesia: from pre-clinical models to clinical studies EE Tsermpini, S Redenšek, V Dolžan Frontiers in pharmacology 12, 834129, 2022 | 7 | 2022 |
| The role of pharmacogenomics in the personalization of Parkinson's disease treatment S Redenšek, V Dolžan Pharmacogenomics 21 (14), 1033-1043, 2020 | 6 | 2020 |
| Genetic variability of the vitamin D receptor affects susceptibility to Parkinson’s disease and dopaminergic treatment adverse events S Redenšek, T Kristanc, T Blagus, M Trošt, V Dolžan Frontiers in aging neuroscience 14, 853277, 2022 | 5 | 2022 |
| Effects of genetic variability in dopaminergic pathway on treatment response in Parkinson's disease S Redenšek, M Trošt, V Dolžan Parkinson's Disease, ed Yenisett SC (Rijeka: IntechOpen;), 27-47, 2018 | 5 | 2018 |
| Investigation of Paraoxonase-1 Genotype and Enzyme-Kinetic Parameters in the Context of Cognitive Impairment in Parkinson’s Disease B Petrič, S Redenšek Trampuž, V Dolžan, M Gregorič Kramberger, ... Antioxidants 12 (2), 399, 2023 | 4 | 2023 |
| An Interdisciplinary Approach to Psoriasis A Chiriac | 3 | 2017 |
| Nanoscale Bilirubin Analysis in Translational Research and Precision Medicine by the Recombinant Protein HUG P Sist, F Tramer, A Bandiera, R Urbani, S Redenšek Trampuž, V Dolžan, ... International Journal of Molecular Sciences 24 (22), 16289, 2023 | 1 | 2023 |
| Case report: application of pharmacogenetics in the personalized treatment of an elderly patient with a major depressive episode M Pjevac, S Redenšek Trampuž, T Blagus, V Dolžan, J Bon Frontiers in Psychiatry 14, 1250253, 2023 | 1 | 2023 |
| Serotonin-related functional genetic variants affect the occurrence of psychiatric and motor adverse events of dopaminergic treatment in Parkinson’s disease: a retrospective … S Redenšek, T Blagus, M Trošt, V Dolžan Journal of personalized medicine 12 (2), 266, 2022 | 1 | 2022 |
| Assessment of the telomere length and its effect on the symptomatology of Parkinson’s disease. Antioxidants 2021; 10: 137 T Levstek, S Redenšek, M Trošt, V Dolžan, KT Podkrajšek PUBMED, 2021 | 1 | 2021 |
